Company news
Nuvalent, Inc. news in 2023
Nuvalent, Inc.'s news releases, calls and decks from 2023, newest first.
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
November 13, 2023
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
October 31, 2023
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
October 12, 2023
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
October 3, 2023
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
September 17, 2023
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
September 4, 2023
Nuvalent to Participate in Upcoming September Investor Conferences
August 30, 2023
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
August 9, 2023
Nuvalent to Participate in Upcoming August Investor Conferences
July 31, 2023
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 23, 2023
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
May 10, 2023
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
April 17, 2023
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
March 22, 2023
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
March 13, 2023
Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
February 28, 2023
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023